Kardigan Inc KARD
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $14.79
- Day Range
- $14.38–14.91
- 52-Week Range
- $13.84–26.76
- Bid/Ask
- $14.42 / $14.68
- Shares Outstanding
- 93.50M
- Market Cap
- $1.35B
- Volume/Avg
- 36,170 / 454,554
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Kardigan Inc is a clinical-stage therapeutics company focused on developing medicines for cardiovascular diseases. Its activities include the research and development of targeted therapies for cardiovascular conditions for which no approved treatments currently exist. The company's clinical-stage programs include Danicamtiv, Ataciguat, and Tonlamarsen, which are being developed for cardiovascular disease indications. The company operates and manages its business as a single operating and reportable segment, focused on the discovery and development of novel therapeutic products to treat cardiovascular disease.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- —
- Website
- https://www.kardigan.bio
Valuation
|
Metric
|
KARD
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 2.25 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
KARD
|
|---|---|
Quick Ratio | 8.54 |
Current Ratio | 8.72 |
Interest Coverage | — |
Quick Ratio
KARD
Profitability
|
Metric
|
KARD
|
|---|---|
Return on Assets (Normalized) | −46.14% |
Return on Equity (Normalized) | −1,043.97% |
Return on Invested Capital (Normalized) | −667.72% |
Return on Assets
KARD
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|w%L$!f | LOCK|WmPxl | $128B | |||
| Moderna Inc
MRNA
| LOCK|fCXJgR | LOCK|B&^ | $76B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|&fP#%F | LOCK|%y%qG | $76B | |||
| argenx SE ADR
ARGX
| LOCK|p#C>M< | LOCK|hg | $57B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|^##<Vf? | LOCK|P!H | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|s>Dz!sn | LOCK|BS#^@ | $29B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|@<PF?w$Z | LOCK|<?#!& | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|@@k%vbz | LOCK|<?m | $24B | |||
| Incyte Corp
INCY
| LOCK|!B#S!<< | LOCK|<h | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|GQxz>% | LOCK|yz | $15B |
United States